4.6 Article

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine

期刊

VIRUSES-BASEL
卷 11, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/v11100964

关键词

virus; broad-spectrum antiviral; antiviral agent; drug target; systems biology

类别

资金

  1. European Regional Development Fund, the Mobilitas Pluss Project [MOBTT39]
  2. National Research Foundation of Korea - Korea government (MSIP), Gyeonggi-do [NRF-2014K1A4A7A01074644]
  3. Jane and Aatos Erkko Foundation [170046]
  4. KISTI
  5. National Research Foundation of Korea [2014K1A4A7A01074644] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

Viruses are the major causes of acute and chronic infectious diseases in the world. According to the World Health Organization, there is an urgent need for better control of viral diseases. Repurposing existing antiviral agents from one viral disease to another could play a pivotal role in this process. Here, we identified novel activities of obatoclax and emetine against herpes simplex virus type 2 (HSV-2), echovirus 1 (EV1), human metapneumovirus (HMPV) and Rift Valley fever virus (RVFV) in cell cultures. Moreover, we demonstrated novel activities of emetine against influenza A virus (FLUAV), niclosamide against HSV-2, brequinar against human immunodeficiency virus 1 (HIV-1), and homoharringtonine against EV1. Our findings may expand the spectrum of indications of these safe-in-man agents and reinforce the arsenal of available antiviral therapeutics pending the results of further in vitro and in vivo tests.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据